Aldeyra Therapeutics, Inc. Common Stock ALDX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T00:20:51.237Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:27:14.914767923Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T00:20:50.845780+00:00
Aldeyra Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.00 | 208.6% | 65.3% | |||
| 25Δ | 0.96 | 255.0% | 65.0% | |||
| 30Δ | 0.92 | 301.4% | 64.7% | |||
| 35Δ | 0.88 | 347.7% | 64.4% | |||
| 40Δ | 0.84 | 394.1% | 64.0% | |||
| 45Δ | 0.80 | 440.5% | 63.7% | |||
| 50Δ | 0.76 | 486.9% | 63.4% | |||
| 55Δ | 0.72 | 533.3% | 63.1% | 1.13 | 433.3% | 19.4% |
| 60Δ | 0.69 | 579.6% | 62.8% | 1.81 | 555.8% | 19.4% |
| 65Δ | 0.65 | 626.0% | 62.5% | |||
| 70Δ | 0.61 | 672.4% | 62.2% | |||
| 75Δ | 0.57 | 718.8% | 61.8% | |||
| 80Δ | 0.53 | 765.1% | 61.5% | |||
20Δ
- Pseudo strike
- 1.00
- IV
- 208.6%
- B/E move
- 65.3%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 0.96
- IV
- 255.0%
- B/E move
- 65.0%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 0.92
- IV
- 301.4%
- B/E move
- 64.7%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 0.88
- IV
- 347.7%
- B/E move
- 64.4%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 0.84
- IV
- 394.1%
- B/E move
- 64.0%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 0.80
- IV
- 440.5%
- B/E move
- 63.7%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 0.76
- IV
- 486.9%
- B/E move
- 63.4%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 0.72
- IV
- 533.3%
- B/E move
- 63.1%
- Pseudo strike
- 1.13
- IV
- 433.3%
- B/E move
- 19.4%
60Δ
- Pseudo strike
- 0.69
- IV
- 579.6%
- B/E move
- 62.8%
- Pseudo strike
- 1.81
- IV
- 555.8%
- B/E move
- 19.4%
65Δ
- Pseudo strike
- 0.65
- IV
- 626.0%
- B/E move
- 62.5%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 0.61
- IV
- 672.4%
- B/E move
- 62.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 0.57
- IV
- 718.8%
- B/E move
- 61.8%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 0.53
- IV
- 765.1%
- B/E move
- 61.5%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
ALEC
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco,…
More →ALLO
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The…
More →ALMS
Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive,…
More →ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered…
More →ALT
Description unavailable
More →ALXO
Description unavailable
More →